Saptalis Drug Patent Portfolio
Saptalis owns 2 orange book drugs protected by 4 US patents Given below is the list of Saptalis's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11541035 | Oral formulations of metronidazole and methods of treating an infection using same | 04 Oct, 2039 | Active |
| US12257236 | Oral formulations of metronidazole and methods of treating an infection using same | 16 Jan, 2039 | Active |
| US5733569 | Galenic compositions comprising calcitonin and their use | 31 Mar, 2015 | Expired |
| US5759565 | Galenic compositions comprising calcitonin and their use | 31 Mar, 2015 | Expired |
Latest Legal Activities on Saptalis's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Saptalis.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Email Notification | 25 Mar, 2025 | US12257236 |
| Recordation of Patent Grant Mailed | 25 Mar, 2025 | US12257236 |
| Recordation of Patent eGrant | 25 Mar, 2025 | US12257236 |
| Patent eGrant Notification | 25 Mar, 2025 | US12257236 |
| Mail Patent eGrant Notification | 25 Mar, 2025 | US12257236 |
| Patent Issue Date Used in PTA Calculation | 25 Mar, 2025 | US12257236 |
| Issue Notification Mailed | 05 Mar, 2025 | US12257236 |
| Email Notification | 05 Mar, 2025 | US12257236 |
| Application Is Considered Ready for Issue | 24 Feb, 2025 | US12257236 |
| Dispatch to FDC | 24 Feb, 2025 | US12257236 |
| Issue Fee Payment Verified | 21 Feb, 2025 | US12257236 |
| Issue Fee Payment Received | 21 Feb, 2025 | US12257236 |
| Change in Power of Attorney (May Include Associate POA) | 23 Dec, 2024 | US12257236 |
| Email Notification | 23 Dec, 2024 | US12257236 |
| Mail Notice of Allowance | 21 Nov, 2024 | US12257236 |
Saptalis's Drug Patent Litigations
Saptalis's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on May 23, 1994, against patent number US5759565. The petitioner , challenged the validity of this patent, with AZRIA et al as the respondent. Click below to track the latest information on how companies are challenging Saptalis's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US5759565 | May, 1994 |
Decision
(25 Aug, 1997)
| AZRIA et al | |
Saptalis's Family Patents
Saptalis Drug List
Given below is the complete list of Saptalis's drugs and the patents protecting them.
1. Likmez
Likmez is protected by 2 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11541035 | Oral formulations of metronidazole and methods of treating an infection using same |
04 Oct, 2039
(13 years from now)
| Active |
| US12257236 | Oral formulations of metronidazole and methods of treating an infection using same |
16 Jan, 2039
(12 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Likmez's drug page
2. Miacalcin
Miacalcin is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5733569 | Galenic compositions comprising calcitonin and their use |
31 Mar, 2015
(11 years ago)
| Expired |
| US5759565 | Galenic compositions comprising calcitonin and their use |
31 Mar, 2015
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Miacalcin's drug page